Trial Information
An Open-Label Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after PD-1/PD-L1 Immune Checkpoint Inhibitors
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724